Immacolata Prevenzano

Immacolata Prevenzano

Auto-generated profile, based on publicly available information

Immacolata Prevenzano

Department of Translational Medical Sciences University of Naples Federico II Naples Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in EMBO Reports
Verified
Journal Article
Closed access
IPImmacolata Prevenzano
Immacolata Prevenzano
ALalessia leone
alessia leone
MLMichele Longo
Michele Longo
ANANTONELLA NICOLO
ANTONELLA NICOLO
SCSerena Cabaro
Serena Cabaro
CNCecilia Nigro
Cecilia Nigro

7 October 2024 in The FASEB Journal
Verified
Journal Article
Open access
ADAntonella Desiderio
Antonella Desiderio
MPMonica Pastorino
Monica Pastorino
MCMichele Campitelli
Michele Campitelli
IPImmacolata Prevenzano
Immacolata Prevenzano
FPFatima Domenica Elisa De Palma
Fatima Domenica Elisa De Palma
FBFrancesco Beguinot
Francesco Beguinot
The risk of developing type 2 diabetes (T2D) is heterogeneous among individuals with obesity. Functional decline of adipocyte precursor cells (APCs) and accumulation of senescent cells in the subcutaneous adipose tissue contributes to the progression toward T2D. LncRNAs regulate cell senescence and may be implicated in determining this abnormality in APCs. Here, we report that APCs from individuals with obesity show a gradual increase in multiple senescence markers, which worsens in parallel with the progression from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) or T2D. Transcriptomic analysis identified PANDAR as the top‐ranked lncRNA differentially expressed in APCs from individuals with obesity and T2D and non‐obese subjects. Q‐PCR confirmed PANDAR up‐regulation in APCs from individuals with obesity, at progressively increased levels in those who developed, respectively, IGT and T2D. Bisulfite sequencing and luciferase assays revealed that, in parallel with glucose tolerance deterioration, the −1317 CpG at the PANDAR promoter became hypo‐methylated in obesity, resulting in enhanced PANDAR induction by p53. PANDAR silencing in senescent APCs from individuals with obesity and T2D caused repression of senescence programs and cell cycle re‐entry. PANDAR transcription in white blood cells (WBCs) mirrored that in APCs. Also, individuals with obesity exhibited rescue of PANDAR transcription in WBCs following bariatric surgery, accompanied by enhanced methylation at the regulatory PANDAR −1317 CpG. In conclusion, PANDAR dysregulation is a newly identified mechanism determining the early senescence of APCs from individuals with obesity, which worsens along the progression toward T2D. In the future, PANDAR targeting may represent a valuable strategy to delay this progression.

7 March 2026 in The FASEB Journal
Verified
Journal Article
Open access
ACAlessandra Croce
Alessandra Croce
PMPaola Mirra
Paola Mirra
FPFrancesca Chiara Pignalosa
Francesca Chiara Pignalosa
FZFederica Zatterale
Federica Zatterale
IPImmacolata Prevenzano
Immacolata Prevenzano
FFFrancesca Fiory
Francesca Fiory
Dopamine (DA) homeostasis is crucial for several relevant body functions, including cognition. Diabetes mellitus (DM) is characterized by both cognitive decline and dopaminergic dysfunction. Methylglyoxal (MGO), a reactive neurotoxic dicarbonyl, which accumulates in DM, induces dopaminergic dysfunction, contributing to DA depletion, and is associated with cognitive deficit. However, the molecular mechanisms underlying MGO impact on dopaminergic function are still unknown. This study aims to clarify how MGO damages the dopaminergic system, analyzing the contribution of miRNAs in its deleterious effect in SH‐SY5Y cells. We found that treatment with MGO significantly reduces the intracellular DA content, increasing the expression of proteins known to negatively affect DA amount, such as COMT (Catechol‐O‐methyltransferase), MAO (Monoamine oxidase), and α‐Syn (α‐synuclein), encoded by the SNCA gene. This was paralleled by a significant reduction in the expression of miR‐190a and miR‐214, known to be regulated by MGO in other cellular models. We found, by TARGETSCAN analysis, that these two miRNAs are predicted regulators of COMT and SNCA. Gain‐ and loss‐of‐function experiments highlighted that these miRNAs are able to modulate the expression of these proteins. We also showed that COMT is a direct target of both miR‐190a and miR‐214, while SNCA is a direct target of miR‐190a and an indirect target for miR‐214. Importantly, the transfection of miR‐190a and miR‐214 specific mimics reverted MGO effects on COMT and α‐Syn expression and restored DA intracellular content. Thus, these miRNAs could represent innovative pharmacological targets for the treatment of DM‐associated dopaminergic dysfunction and cognitive decline.